CLOSE ×
    Documents | High Throughput 96-well purification of biopharmaceuticals for cell-based screening

    High Throughput 96-well purification of biopharmaceuticals for cell-based screening

    Introduction

    Cambridge Antibody Technology (CAT) uses its proprietary Phage Display and Ribosome Display technologist to isolate therapeutic antibodies rapidly. Its human antibody libraries contain up to 1014 entities that are selected against a target antigen, producing approximately 105 samples for screening. Screens use biochemical and cell-based assays to identify biologically active antibodies, most with homogeneous or heterogeneous non-radioactive assays.

    Download Options

    Select document language:
    Download E-mail a Copy High Throughput 96-well purification of biopharmaceuticals for cell-based screening